US2020271674A1PendingUtilityA1

Serum Biomarker Screen for the Diagnosis of Clinical and Preclinical Alzheimer's Disease

40
Individually held — no corporate assignee on recordPriority: Jul 16, 2012Filed: Mar 25, 2020Published: Aug 27, 2020
Est. expiryJul 16, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Donald R. RoyallRaymond F. Palmer
G01N 2800/60G01N 33/6896
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Certain embodiments are directed to methods of identifying dementia in subjects comprising, measuring serum levels of one or more of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor and identifying a subject as having dementia if the levels of the biomarkers is increased.

Claims

exact text as granted — not AI-modified
1 - 9 . (canceled) 
     
     
         10 . A method for treating a human subject comprising,
 (a) obtaining a blood sample from said subject;   (b) contacting the biological sample with reagents that specifically bind and form a complex with IL-13 and alpha 2 macroglobulin biomarkers forming a reagent biomarker complex;   (c) detecting the reagent biomarker complex of IL-13 and alpha 2 macroglobulin and determining the level of the biomarkers in the sample; and   (d) administering treatment to the subject when the level of the biomarkers in the sample is increased with respect to a control level.   
     
     
         11 . The method of claim  1 , comprising treating a mild cognitive impairment (MCI) condition. 
     
     
         12 . The method of claim  1 , comprising treating a dementia condition. 
     
     
         13 . The method of claim  3 , comprising treating an early stage dementia condition. 
     
     
         14 . The method of claim  1 , further comprising identifying dementia in said subject based on the step of determining the level of said biomarkers. 
     
     
         15 . The method of claim  5 , comprising identifying early stage dementia in said subject by determining increased serum levels of any of interferon gamma, IL-10, IL-12p40, IL-13, alpha 2 macroglobulin, beta 2 microglobulin, pancreatic polypeptide, prolactin, stem cell factor, thrombopoietin, and Von Willebrand Factor for dementia. 
     
     
         16 . The method of claim  1 , further comprising selecting said biomarkers based on a linear regression. 
     
     
         17 . The method of claim  1 , wherein said biomarkers are independent of an ethnicity of said subject.

Join the waitlist — get patent alerts

Track US2020271674A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.